ADMA Biologics, Inc.
ADMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, ADMA Biologics, Inc. (ADMA) is listed under Biotechnology. The company carries a $2.14B market cap, placing it firmly in the mid-cap category. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Market Cap
$2.14B
Beta
0.77
P/E (TTM)
13.63
P/E (Fwd)
9.71
EPS (TTM)
$0.70
EPS (Fwd)
$0.98
ROE
41.9%
ROA
21.8%
Cash
$55.92B
Total Debt
$97.67B
Free CF
$54.8M
52W Change
-41.3%
Annual Financials
Cash vs Debt
Where ADMA stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, ADMA finished 13.97% below its 150-day moving average ($11.02) and 26.11% below its 200-day moving average ($12.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADMA overbought or oversold?
At the August 28, 2026 close, ADMA's RSI(14) was 42.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ADMA has $55.92B in cash with $97.67B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $54.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 41.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 21.8% further supports the picture of efficient asset utilization. Revenue has grown from $154.1M (2022) to $510.2M (2025), reflecting a 231% increase over the period.
Investors considering ADMA Biologics, Inc. should weigh the typical risks associated with ADMA's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ADMA Biologics, Inc.'s trajectory.